Tag: TGF-beta signaling
-
![Acceleron (XLRN.Q) gains $1.3 billion in market cap after successful phase ll trial]()
Acceleron (XLRN.Q) gains $1.3 billion in market cap after successful phase ll trial
Acceleron is finding solutions for serious and rare diseases. It has a pipeline of products moving towards commercialisation, including a co-promotion with the $152 billion Bristol-Myers Squibb (BMY.NYSE)
